Novartis | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
AbbVie USD 3.86B 306M 2024-12
Alcon AG USD 802M 7M 2024-12
Almirall EUR -50222000 162.22M 2024-06
Amgen USD 1.88B 253M 2024-12
AstraZeneca USD 5.55B 307M 2024-12
Autolus Therapeutics Ltd 27.33M 5.43M 2024-09
Bayer EUR 4.34B 610M 2024-12
Biogen USD 677.3M 99.6M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Fresenius EUR 769M 68M 2024-12
Fresenius Medical Care EUR 840M 84M 2024-12
Galapagos EUR 41.25M 11.98M 2024-12
Genmab DKK 1.25B 384M 2024-12
Gilead Sciences USD 1.86B 451M 2024-12
GlaxoSmithKline GBP 2.66B 1.14B 2024-12
GRIFOLS EUR 269.48M 49.95M 2024-12
Hikma Pharmaceutical USD 280M 4M 2024-06
J&J USD 6.45B 975M 2024-12
Merck EUR 1.41B 72M 2024-09
Merck USD 2.85B 148M 2024-12
Novartis USD 3.5B 368M 2024-12
Novartis USD 3.5B 368M 2024-12
Novo Nordisk 16.59B 501M 2024-09
Orion EUR 114.9M 29.1M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Philips EUR 1.33B 99M 2024-12
Recordati EUR 149.34M 15.49M 2024-09
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Sanofi EUR 2.68B 26M 2024-09
UCB EUR 533M 434M 2024-06



Novartis Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.